Related Experiment Video
Updated: Dec 29, 2025
Author Spotlight: Developing a Bedside Protocol for Kidney and Genitourinary Ultrasonography
Published on: June 21, 2024
Structured patient care pathway for gout
Insights
A structured gout care pathway effectively lowers serum urate levels, significantly reducing painful arthritis flares. This approach ensures patients achieve treatment goals, improving long-term joint health and preventing chronic gout complications.
Area of Science:
- Rheumatology
- Clinical Medicine
- Pharmacology
Background:
- Inadequate pharmacological treatment and follow-up for gout increase patient risk of recurrent arthritis flares.
- Untreated or poorly managed gout can lead to chronic tophaceous gout and irreversible joint damage.
Purpose of the Study:
- To evaluate the effectiveness of a structured care pathway for gout management.
- To assess the achievement of serum urate level targets and reduction in arthritis flares.
Main Methods:
- Implementation of a structured care pathway involving preventive medication (primarily allopurinol) and regular monitoring.
- Setting treatment goals for serum urate concentration (below 360 µmol/l or 300 µmol/l for tophaceous gout).
- Continuous data collection on patient outcomes and treatment adherence.
Main Results:
- 83% of gout patients achieved their target serum urate levels within six months of initiating urate-lowering therapy.
- Following treatment goal achievement, 70% of patients remained free of arthritis flares.
- The average serum urate level at inclusion was 446 µmol/l, indicating a significant baseline level of hyperuricemia.
Conclusions:
- A standardized gout care pathway, incorporating regular monitoring and adaptive preventive treatment, is highly effective.
- Achieving target serum urate levels through this pathway is crucial for preventing painful arthritis flares and managing gout effectively.
Background:
Pharmacological treatment and follow-up of gout is often inadequate.The patients risk repeated, painful arthritis flares and some develop chronic tophaceous gout and joint damage.
Material And Method:
Since 1 March 2017, a structured care pathway has been established for patients with gout at the Department of Rheumatology, Haukeland University Hospital. Patients were placed on preventive medication, the majority on allopurinol, and were regularly monitored. Patient education is key to the care pathway. The treatment goal is to lower the concentration of serum urate to a level below a defined threshold value (360 µmol/l for non-tophaceous gout or 300 µmol/l for tophaceous gout). Patient data were collected on a continuous basis and recorded in a research database. The care pathway is assessed after 18 months.
Results:
A total of 103 patients have been included, of whom 93 (90 %) are men, with an average age of 63 years and large variations in duration of the disease (min.-max. 0-36 years). Eight patients left the care pathway during the project. The average level of serum urate at inclusion was 446 µmol/l (min.-max. 144-751 µmol/l). The average maximum dose of allopurinol was 333 mg (min.-max. 100-700 mg). Survival analysis showed that three months after the start of urate-lowering therapy, 49 % of the patients had achieved their analytical treatment goal. Altogether 83 % achieved the goal within six months. The majority (70 %) were free of flares after achieving the treatment goal.
Interpretation:
A standardised care pathway for gout enables adaptation of preventive treatment through regular monitoring. The care pathway helps the vast majority of patients to achieve treatment goals, which is crucial to avoid arthritis flares.
Related Concept Videos
01:28Urinary Tract Calculi V: Nursing Management
01:27Peripheral Artery Disease III: Interprofessional Care
01:28Chronic Kidney Disease III: Interprofessional Care
01:26Peripheral Artery Disease IV: Nursing Management
01:26Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
01:30Urinary Tract Calculi III: Medical Management